Abstract
The earlier prediction that more cases of PML would be identified in association with natalizumab treatment has been realized, and we have no clear idea how many cases are on the horizon or how to anticipate which patients will be at greatest risk. Eugene Major writes that knowing that a patient has elevated levels of CD34+ cells, viremia, or both could be informative for the evaluation of continued or future treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
